Literature DB >> 12215889

Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model.

H Nakamura1, M Aoki, K Tamai, M Oishi, T Ogihara, Y Kaneda, R Morishita.   

Abstract

Atopic dermatitis, a chronic inflammatory skin disease characterized by relapsing eczema and intense prurigo, requires effective and safe pharmacological therapy. In this study, we examined the efficacy of ointment containing NF-kB decoy oligodeoxynucleotides (ODN) on atopic dermatitis lesions in NC/Nga mice, which are characterized by the spontaneous onset of atopic dermatitis in conventional conditions. Topical administration of NF-kB decoy ODN twice a month resulted in a significant reduction in clinical skin condition score and marked improvement of histological findings. Reduction of the atopic skin condition by NF-kB decoy ODN was accompanied by a significant decrease in migration of mast cells into the dermis and an increase in apoptotic cells. Here, we demonstrated the successful treatment of atopic dermatitis with ointment containing NF-kB decoy ODN in a mouse model, promising new therapy for atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215889     DOI: 10.1038/sj.gt.3301724

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

1.  Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation.

Authors:  L A O'Reilly; P Hughes; A Lin; P Waring; U Siebenlist; R Jain; D H D Gray; S Gerondakis; A Strasser
Journal:  Cell Death Differ       Date:  2014-10-31       Impact factor: 15.828

2.  Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.

Authors:  Joe Inoue; Satoshi Yotsumoto; Takatoshi Sakamoto; Seishi Tsuchiya; Yukihiko Aramaki
Journal:  Pharm Res       Date:  2005-09-26       Impact factor: 4.200

3.  Tumor necrosis factor α-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor κB.

Authors:  Claus Johansen; Jette L Riis; Anne Gedebjerg; Knud Kragballe; Lars Iversen
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

4.  Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge.

Authors:  Mei Ming; Baozhong Zhao; Christopher R Shea; Palak Shah; Lei Qiang; Steven R White; Diane M Sims; Yu-Ying He
Journal:  J Allergy Clin Immunol       Date:  2014-11-07       Impact factor: 10.793

5.  Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.

Authors:  Christopher G De Vry; Srinivasa Prasad; Laszlo Komuves; Carlos Lorenzana; Christi Parham; Tina Le; Sarvesh Adda; Jennifer Hoffman; Nicole Kahoud; Radhika Garlapati; Radha Shyamsundar; Kim Mai; Jie Zhang; Tony Muchamuel; Maya Dajee; Brian Schryver; Leslie M McEvoy; Rolf O Ehrhardt
Journal:  Gut       Date:  2006-09-01       Impact factor: 23.059

6.  Suppression of wear-particle-induced pro-inflammatory cytokine and chemokine production in macrophages via NF-κB decoy oligodeoxynucleotide: a preliminary report.

Authors:  Tzu-Hua Lin; Zhenyu Yao; Taishi Sato; Michael Keeney; Chenguang Li; Jukka Pajarinen; Fan Yang; Kensuke Egashira; Stuart B Goodman
Journal:  Acta Biomater       Date:  2014-05-09       Impact factor: 8.947

Review 7.  Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target.

Authors:  Tzu-hua Lin; Yasunobu Tamaki; Jukka Pajarinen; Heather A Waters; Deanna K Woo; Zhenyu Yao; Stuart B Goodman
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

Review 8.  Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement.

Authors:  S B Goodman; E Gibon; J Pajarinen; T-H Lin; M Keeney; P-G Ren; C Nich; Z Yao; K Egashira; F Yang; Y T Konttinen
Journal:  J R Soc Interface       Date:  2014-01-29       Impact factor: 4.118

Review 9.  Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.

Authors:  Sander W Tas; Margriet J B M Vervoordeldonk; Paul P Tak
Journal:  Curr Gene Ther       Date:  2009-06       Impact factor: 4.391

10.  Cancer immunotherapy using the Fusion gene of Sendai virus.

Authors:  Jiayu A Tai; Chin Yang Chang; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Cancer Gene Ther       Date:  2019-08-06       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.